This story from Reuters is outside of my area of expertise so I'm just going to make this blanket recommendation. This is a solid piece of reporting on the not easy-to-cover fields of epidemiology, biostatistics and the economics of health care.
Special Report: Behind a cancer-treatment firm's rosy survival claims
Edit (Joseph): Andrew Gelman correctly points out that the authors are Sharon Begley and Robin Respaut. This report is useful to me as another reason that we need to have a control arm for randomized trials. It isn't enough to know what the rate is for conventional care and contrast a novel therapy with it. You need to also account for the selection effects among the population receiving the novel therapy. Randomization is a very nice way to accomplish this outcome in a generally understood manner.
Error and margin of error
49 minutes ago